Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer

NCT01885949 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01885949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
September 3, 2013
Completion date
May 23, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer